InsidersTradesSigma
Total declarations
Companies
▲ Purchases (20 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
20
Disclosed sells
0
T+90 hit rate
39%
T+90 mean return
+3.7%
Across 18 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by DUGGAN ROBERT W, Chief Executive Officer. Officer active across 3 companies, notably Summit Therapeutics Inc.. Cumulatively, 36 filings have been logged. Split: 20 buys · 0 sell. Total volume traded: €638.4m. Activity tracked since 12 May 2021. The latest transaction was filed on 4 June 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations36 total
100,000 shares@ US$14.600.012% mcap1.3% of flowCommon StockSEC:0001055919-26-000005:0
Ideal exit: 1 Mar 2027 (T+270)
660,233 shares@ US$19.690.65% mcap10.4% of flowCommon StockSEC:0001437749-26-017478:0
Ideal exit: 5 Feb 2027 (T+270)
333,394 shares@ US$17.68Common StockSEC:0001599298-25-000142:0
Ideal exit: 7 Jun 2026 (T+270)
74,545 shares@ US$2.640.0% of flowCommon StockSEC:0001599298-25-000106:0
3,985,055 shares@ US$1.581.1% of flowCommon StockSEC:0001599298-25-000058:0
5,187,824 shares@ US$11.0022.7% of flowCommon StockSEC:0000950170-24-138177:0
55,256 shares@ US$17.180.4% of flowCommon StockSEC:0001437749-24-037766:0
Ideal exit: 9 Sept 2025 (T+270)
45,404 shares@ US$17.130.3% of flowCommon StockSEC:0000950170-24-136901:0
Ideal exit: 8 Sept 2025 (T+270)
6,054 shares@ US$16.740.0% of flowCommon StockSEC:0001437749-24-037509:0
Ideal exit: 7 Sept 2025 (T+270)
3,325,991 shares@ US$22.7012.8% of flowCommon StockSEC:0001599298-24-000139:0
5,187,824 sharesCommon StockSEC:0001437749-24-022358:0
17,999 shares@ US$9.150.1% of flowCommon StockSEC:0001437749-23-034484:0
Ideal exit: 7 Sept 2024 (T+270)
90,118 shares@ US$9.360.3% of flowCommon StockSEC:0001437749-23-034371:0
Ideal exit: 6 Sept 2024 (T+270)
116,656 shares@ US$9.540.4% of flowCommon StockSEC:0001437749-23-034250:0
Ideal exit: 3 Sept 2024 (T+270)
74,852 shares@ US$9.190.3% of flowCommon StockSEC:0001437749-23-034104:0
Ideal exit: 2 Sept 2024 (T+270)
9,933 shares@ US$5.950.0% of flowCommon StockSEC:0001437749-23-034041:0
66,021 shares@ US$9.340.2% of flowCommon StockSEC:0001437749-23-033920:0
Ideal exit: 31 Aug 2024 (T+270)
20,000 shares@ US$10.660.1% of flowCommon StockSEC:0001437749-23-033803:0
45,600 shares@ US$9.070.2% of flowCommon StockSEC:0001437749-23-033705:0
Ideal exit: 27 Aug 2024 (T+270)
152,944 shares@ US$9.060.5% of flowCommon StockSEC:0001437749-23-033556:0
Ideal exit: 26 Aug 2024 (T+270)
1,667 shares@ US$5.950.0% of flowCommon StockSEC:0001437749-23-033434:0
124,397 shares@ US$8.980.4% of flowCommon StockSEC:0001437749-23-033276:0
Ideal exit: 24 Aug 2024 (T+270)
241 shares@ US$6.100.0% of flowCommon StockSEC:0001437749-23-032670:0
Ideal exit: 13 Aug 2024 (T+270)
3,333 shares@ US$5.950.0% of flowCommon StockSEC:0001437749-23-031322:0
1,667 shares@ US$5.950.0% of flowCommon StockSEC:0001437749-23-024790:0
25 of 36 declarations
About DUGGAN ROBERT W
Robert W. Duggan is the Chief Executive Officer and Director of Summit Therapeutics Inc. and PULSE Biosciences, Inc. He is responsible for the strategic direction of these companies, which focus on developing innovative treatments in the healthcare field. His leadership is essential for the growth and innovation of these firms.
